Form 4 for MDGL MADRIGAL PHARMACEUTICALS, INC.
Accepted 2026-03-06 00:00:00 ET · period of report 2026-03-04 · accession 0001628280-26-015775 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-03-06 | 2026-03-06 | MDGL | Dier Mardi | EVP, CFO | S - Sale | $430.87 | -1,982 | 12.8K | -13% | -$854.0K |
| D | 2026-03-06 | 2026-03-04 | MDGL | Dier Mardi | EVP, CFO | A - Grant | $0.00 | +5,215 | 14.5K | +56% | $0 |
| D | 2026-03-06 | 2026-03-04 | MDGL | Dier Mardi | EVP, CFO | A - Grant | $0.00 | +6,519 | 6,519 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-03-06 | S | D | 160 | $434.20 | 12,690 | D | — | — | (F9) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $433.82 to $434.58, inclusive. |
| 2 | Common | Common Stock | 2026-03-06 | S | D | 80 | $435.32 | 12,610 | D | — | — | (F10) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $435.26 to $435.37, inclusive. |
| 3 | Common | Common Stock | 2026-03-06 | S | D | 80 | $436.69 | 12,530 | D | — | — | (F11) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $436.46 to $436.92, inclusive. |
| 4 | Common | Common Stock | 2026-03-06 | S | D | 40 | $437.65 | 12,490 | D | — | — | |
| 5 | Common | Common Stock | 2026-03-04 | A | A | 5,215 | $0.00 | 14,472 | D | — | — | |
| 6 | Common | Common Stock | 2026-03-06 | S | D | 646 | $431.94 | 13,826 | D | — | — | |
| 7 | Common | Common Stock | 2026-03-06 | S | D | 40 | $425.08 | 13,786 | D | — | — | |
| 8 | Common | Common Stock | 2026-03-06 | S | D | 420 | $426.86 | 13,366 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $426.46 to $427.08, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote and the footnotes below. |
| 9 | Common | Common Stock | 2026-03-06 | S | D | 80 | $427.85 | 13,286 | D | — | — | (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $427.50 to $428.19, inclusive. |
| 10 | Common | Common Stock | 2026-03-06 | S | D | 160 | $429.00 | 13,126 | D | — | — | (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $428.51 to $429.24, inclusive. |
| 11 | Common | Common Stock | 2026-03-06 | S | D | 40 | $429.58 | 13,086 | D | — | — | |
| 12 | Common | Common Stock | 2026-03-06 | S | D | 120 | $430.90 | 12,966 | D | — | — | (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $430.66 to $431.04, inclusive. |
| 13 | Common | Common Stock | 2026-03-06 | S | D | 116 | $432.56 | 12,850 | D | — | — | (F8) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $432.41 to $432.99, inclusive. |
| 14 | Derivative | Stock Option (Right to Buy) | 2026-03-04 | A | A | 6,519 | $0.00 | 6,519 | D | $434.80 · — to 2036-03-04 | 6,519 Common Stock | (F12) The option vests as to 25% of the shares on the first anniversary of the date of grant (March 4, 2027) and, thereafter, 6.25% of the shares shall vest on the last day of each successive three-month period, provided the Reporting Person continues in service with the Issuer on each such date. |